Cardiology - Medtelligence

1-16 of 164

Lipids and the Brain: Extending Cardiovascular Risk Reduction to Neurodegenerative Disease
Lipids and the Brain: Extending Cardiovascular Risk Reduction to Neurodegenerative Disease
MinuteCE®
Lipids and the Brain: Extending Cardiovascular Risk Reduction to Neurodegenerative Disease
Christie Ballantyne, MD; Philip Scheltens, MD, PhD
1.00 program credit
- Christie Ballantyne, MD
- Philip Scheltens, MD, PhD
1.00 program credit
Beyond Lipids: Metabolic and Renal Implications of CETP Inhibition
Beyond Lipids: Metabolic and Renal Implications of CETP Inhibition
MinuteCE®
Beyond Lipids: Metabolic and Renal Implications of CETP Inhibition
Erin Michos
1.00 program credit
- Erin Michos
1.00 program credit
Efficacy and Safety Deep Dive What Latest Data Tell Us
Efficacy and Safety Deep Dive What Latest Data Tell Us
MinuteCE®
Efficacy and Safety Deep Dive What Latest Data Tell Us
Christie Ballantyne, MD
1.00 program credit
- Christie Ballantyne, MD
1.00 program credit
MinuteCE®
Advancing Lipid Care: CETP Inhibition and Overcoming Inertia in Modern ASCVD Management
Christie Ballantyne, MD; Erin Michos
1.00 credit 8 episodes
- Christie Ballantyne, MD
- Erin Michos
- Philip Scheltens, MD, PhD
1.00 credit 8 episodes
What Comes Next: Building the Future Lipid Toolbox
What Comes Next: Building the Future Lipid Toolbox
MinuteCE®
What Comes Next: Building the Future Lipid Toolbox
Christie Ballantyne, MD; Erin Michos
1.00 program credit
- Christie Ballantyne, MD
- Erin Michos
1.00 program credit
The Unmet Need in ASCVD: Why Targets Are Still Not Enough
The Unmet Need in ASCVD: Why Targets Are Still Not Enough
MinuteCE®
The Unmet Need in ASCVD: Why Targets Are Still Not Enough
Erin Michos
1.00 program credit
- Erin Michos
1.00 program credit
Obicetrapib: Mechanism Meets Clinical Impact
Obicetrapib: Mechanism Meets Clinical Impact
MinuteCE®
Obicetrapib: Mechanism Meets Clinical Impact
Christie Ballantyne, MD
1.00 program credit
- Christie Ballantyne, MD
1.00 program credit
Beyond LDL-C: Genetic Drivers of Residual Risk in ASCVD
Beyond LDL-C: Genetic Drivers of Residual Risk in ASCVD
MinuteCE®
Beyond LDL-C: Genetic Drivers of Residual Risk in ASCVD
Erin Michos
1.00 program credit
- Erin Michos
1.00 program credit
CETP Inhibition: A Class Reborn
CETP Inhibition: A Class Reborn
MinuteCE®
CETP Inhibition: A Class Reborn
Christie Ballantyne, MD; Erin Michos
1.00 program credit
- Christie Ballantyne, MD
- Erin Michos
1.00 program credit
Potassium Binders to Optimize GDMT Therapy in HFrEF
Potassium Binders to Optimize GDMT Therapy in HFrEF
MinuteCE®
Potassium Binders to Optimize GDMT Therapy in HFrEF
Nihar R. Desai, MD, MPH; Ellie Kelepouris, MD, FACP, FAHA
1.00 program credit
- Nihar R. Desai, MD, MPH
- Ellie Kelepouris, MD, FACP, FAHA
1.00 program credit
Differentiating Oral Potassium Binders: Mechanism, Onset, and Sodium Load
Differentiating Oral Potassium Binders: Mechanism, Onset, and Sodium Load
MinuteCE®
Differentiating Oral Potassium Binders: Mechanism, Onset, and Sodium Load
James Burton, DM, FRCP; Ellie Kelepouris, MD, FACP, FAHA
1.00 program credit
- James Burton, DM, FRCP
- Ellie Kelepouris, MD, FACP, FAHA
1.00 program credit
Personalized Treatment Strategies for Hyperkalemia: Bridging Evidence and Clinical Practice Needs
Personalized Treatment Strategies for Hyperkalemia: Bridging Evidence and Clinical Practice Needs
MinuteCE®
Personalized Treatment Strategies for Hyperkalemia: Bridging Evidence and Clinical Practice Needs
Ellie Kelepouris, MD, FACP, FAHA
1.00 program credit
- Ellie Kelepouris, MD, FACP, FAHA
1.00 program credit
CKD, Diabetes, and Albuminuria: Keeping Kidney-Protective Therapy on Board Despite Hyperkalemia
CKD, Diabetes, and Albuminuria: Keeping Kidney-Protective Therapy on Board Despite Hyperkalemia
MinuteCE®
CKD, Diabetes, and Albuminuria: Keeping Kidney-Protective Therapy on Board Despite Hyperkalemia
Ellie Kelepouris, MD, FACP, FAHA; Pauline A. Swift, PhD
1.00 program credit
- Ellie Kelepouris, MD, FACP, FAHA
- Pauline A. Swift, PhD
1.00 program credit
The Edema Question: Selecting a Potassium Binder in Patients With HF or Congestion
The Edema Question: Selecting a Potassium Binder in Patients With HF or Congestion
MinuteCE®
The Edema Question: Selecting a Potassium Binder in Patients With HF or Congestion
Nihar R. Desai, MD, MPH; Pauline A. Swift, PhD
1.00 program credit
- Nihar R. Desai, MD, MPH
- Pauline A. Swift, PhD
1.00 program credit
The Binder Selection Playbook: Matching the Right Strategy to the Right Patient
The Binder Selection Playbook: Matching the Right Strategy to the Right Patient
MinuteCE®
The Binder Selection Playbook: Matching the Right Strategy to the Right Patient
James Burton, DM, FRCP; Nihar R. Desai, MD, MPH
1.00 program credit
- James Burton, DM, FRCP
- Nihar R. Desai, MD, MPH
1.00 program credit
MinuteCE®
The Potassium Shift: Individualizing Hyperkalemia Management With Modern Oral Potassium Binders
James Burton, DM, FRCP; Nihar R. Desai, MD, MPH
1.00 credit 8 episodes
- James Burton, DM, FRCP
- Nihar R. Desai, MD, MPH
- Ellie Kelepouris, MD, FACP, FAHA
- Pauline A. Swift, PhD
1.00 credit 8 episodes

Prev
1
2
3
…
10
11
Next

1/6